Detailed explanation of the official instructions for Tislelizumab

Tislelizumab (Tislelizumab) is a PD-1 monoclonal antibody immune checkpoint inhibitor developed by BeiGene (BeiGene) and is used for the treatment of various malignant tumors. It blocks the binding of programmed cell death receptor 1 (PD-1) and its ligand PD-L1/PD-L2, thereby restoring the immune killing ability of T cells against tumor cells. The following will be combined with the official instructions of tislelizumab to comprehensively analyze the indications, mechanism of action, usage and dosage, adverse reactions and precautions of this drug.

1. Indications and approval status

According to the official instructions, tislelizumab has been approved in China for the following indications:

Patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) who have failed platinum-based chemotherapy.

Patients with classic Hodgkin lymphoma (cHL) after failure of at least second-line systemic therapy.

Locally advanced or metastatic urothelial carcinoma that has failed previous systemic therapy.

In combination with chemotherapy, it is used in the first-line treatment of non-squamous NSCLC.

Other studies include various solid tumors such as hepatocellular carcinoma, gastric cancer, and esophageal cancer, and some indications are still in the clinical trial stage.

Tislelizumab has shown good tolerability and immune response rates in different indications, especially in some refractory tumors, providing patients with new treatment options.

2. Mechanism of action

Tislelizumab is a humanized IgG4 antibody specifically designed to weaken binding to Fcγ receptors, thereby reducing antibody-dependent phagocytosis (ADCP) and preventing T cells from being cleared by macrophages. It blocks PD-1 and its ligands by binding to TPD-1 receptors on the cell surface. PD-L1 and PD-L2 combine to relieve the inhibitory state of T cells and restoreAntitumor activity of T cells.

Unlike some first-generation PD-1 antibodies, tislelizumab is structurally optimized to improve antibody stability, reduce off-target effects and enhance anti-tumor activity.

3. Usage and dosage

The recommended dose of tislelizumab is: 200mg intravenously, once every three weeks (Q3W).

It needs to be diluted to 100ml sodium chloride injection before injection, and the intravenous infusion time should be no less than 30 minutes. Treatment should be continued until disease progression or unacceptable toxicity occurs. There may be dose and cycle adjustments for certain indications (such as combined use with chemotherapy), which should be judged by the doctor based on the specific treatment plan.

4. Adverse reactions

According to the instructions and clinical data, most of the adverse reactions of tislelizumab are mild to moderate and controllable. Common adverse reactions include:

Fatigue, loss of appetite, rash, diarrhea, fever;

Abnormal laboratory indicators, such as elevated transaminases, elevated creatinine, and thyroid dysfunction;

Immune-related adverse events (irAEs): including thyroiditis, pneumonia, hepatitis, colitis, etc.

Although serious adverse reactions are uncommon, high vigilance is required, such as immune pneumonia and liver function damage. Once they occur, the medication should be suspended or terminated and glucocorticoid treatment should be given. During treatment, it is recommended to regularly monitor thyroid, liver and kidney function, blood sugar and other indicators.

5. Taboos and Precautions

There are no clear absolute contraindications listed in the instructions, but use with caution or follow doctor's advice in the following situations:

Patients with active autoimmune diseases;

Patients after organ transplantation or allogeneic hematopoietic stem cell transplantation;

patients taking immunosuppressants;

Pregnant and lactating women: Animal studies have shown that tislelizumab may have effects on the fetus, and the benefits and risks should be weighed when using it;

Patients with co-infections (such as active tuberculosis, active hepatitis B virus replication) should assess the risk before deciding whether to use it.

In addition, tislelizumab may cause delayed adverse reactions, which may still occur even months after discontinuation of treatment, and long-term follow-up should be strengthened.

6. Drug interactions and combination therapy

As an immunotherapy drug, tislelizumab needs to consider the risk of additive toxicity when used in combination with chemotherapy and targeted drugs. For example, when combined with pemetrexed or cisplatin, reactions such as bone marrow suppression, abnormal liver and kidney function, etc. need to be closely observed. There is still insufficient evidence to show the clear benefit of combining tislelizumab with other immunotherapy drugs, so the combination regimen must be strictly conducted within the framework of clinical research.

7. Storage and Preparation

Drugs should be kept refrigerated at 2°C to 8°C, avoiding freezing and strong light exposure. It should be used within the specified time after preparation to avoid bacterial contamination.

To sum up, tislelizumab, as a representative drug of domestically produced PD-1 immunotherapy, occupies an increasingly important position in clinical tumor treatment due to its good efficacy, safety and high accessibility. It is a trusted immunotherapy option for patients with wild-type EGFR, NSCLC, Hodgkin lymphoma, and urothelial carcinoma. During use, management should be strictly in accordance with the instructions and doctor's guidance to ensure efficacy and patient safety. In the future, with in-depth research, its indications are expected to be further expanded and benefit more patients.

Reference materials:https://www.drugs.com/donanemab.html